Neumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research report released on Friday,Benzinga reports. The brokerage currently has a $30.00 price objective on the stock.

Several other analysts have also recently weighed in on NMRA. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Royal Bank of Canada cut Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $29.00 to $4.00 in a report on Thursday, January 2nd. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, January 2nd. JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Finally, Bank of America decreased their price objective on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Neumora Therapeutics Stock Up 3.0 %

NASDAQ:NMRA opened at $1.74 on Friday. The business’s 50-day moving average price is $5.34 and its two-hundred day moving average price is $9.78. Neumora Therapeutics has a twelve month low of $1.60 and a twelve month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter in the previous year, the firm earned ($1.14) earnings per share. On average, analysts expect that Neumora Therapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Neumora Therapeutics during the 4th quarter worth approximately $61,000. PNC Financial Services Group Inc. bought a new position in Neumora Therapeutics during the 4th quarter worth approximately $64,000. Quantbot Technologies LP bought a new position in Neumora Therapeutics during the 4th quarter worth approximately $92,000. PEAK6 LLC bought a new position in Neumora Therapeutics during the 4th quarter worth approximately $117,000. Finally, EntryPoint Capital LLC bought a new position in Neumora Therapeutics during the 4th quarter worth approximately $135,000. 47.65% of the stock is currently owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.